In certain genetic variants, there could be a predominant pathway involved (neuroinflammation in LRRK2 mutation carriers, or α-synuclein overaccumulation in glucocerebrosidase [GBA] mutation carriers); however, in this study, we used cells from an individual with idiopathic PD, having ruled out all known generic variants. This evidence concerns the gene GBA1 and Parkinson disease.